The different patterns of blood pressure elevation by rofecoxib and nabumetone

Reitblat, Tatiana; Zamir, D; Estis, L; Priluk, R.; Drogenikov, T; Viskoper, J. R.

doi:10.1038/sj.jhh.1001411

Cited by 15 publications

(4 citation statements)

References 15 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The blood pressure observations in this study are generally in accordance with those from another placebo-controlled efficacy trial of patients with OA of the knee or hip in which 3 doses of AZD3582 were compared with rofecoxib 25 mg/ day (31). Specific studies with blood pressure as the primary measure over a 24-hour period are required to confirm any effect of AZD3582 on blood pressure and to establish the clinical relevance of this effect vis a vis the effects of NSAIDs and coxibs (32,33).…”

Section: Discussionmentioning

confidence: 58%

Comparison of the COX‐inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee

Schnitzer¹,

Kivitz²,

Lipetz³

et al. 2005

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To compare the efficacy, safety, and tolerability of AZD3582 with that of rofecoxib, naproxen, and placebo in patients with osteoarthritis (OA) of the knee, and to define the dosage of AZD3582 (125 mg, 375 mg, and 750 mg twice a day) that is noninferior in efficacy to rofecoxib. Methods. A double-blind study of 672 patients with OA of the knee was conducted. Patients who experienced increased pain on withdrawal of analgesia were randomized to receive AZD3582 125 mg, 375 mg, or 750 mg twice a day; rofecoxib 25 mg once a day; naproxen 500 mg twice a day; or placebo for 6 weeks. Efficacy, tolerability, and safety were monitored throughout the study. The primary variable was the change in Western Ontario and McMaster Universities Osteoarthritis Index pain subscale from baseline to the mean of weeks 4 and 6, comparing AZD3582 with placebo for superiority and with rofecoxib for noninferiority using a predefined margin of 10 mm.

show abstract

Section: Discussionmentioning

confidence: 58%

Comparison of the COX‐inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee

Schnitzer¹,

Kivitz²,

Lipetz³

et al. 2005

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…No significant difference between agents on renal sodium excretion or systolic blood pressure (measured 2–4 times per day) was observed, although sodium retention and blood pressure were increased as compared with the placebo group. Finally, hypertensive OA patients with controlled blood pressure received either 25 mg rofecoxib once daily or namebutone 2000 mg once daily for 1 week of treatment and 1000 mg for the following 3 weeks [45]. Twenty‐four hour arterial blood pressure monitoring was performed.…”

Section: Blood Pressure Effects Of Coxibsmentioning

confidence: 99%

Adverse renal effects of anti‐inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors

Gambaro

Perazella

2003

Journal of Internal Medicine

191

119

View full text Add to dashboard Cite

. Gambaro G, Perazella MA (Division of Nephrology, University Hospital, Padua, Italy; and Section of Nephrology, Yale University, New Haven, CT, USA). Adverse renal effects of anti‐inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors (Review). J Intern Med 2003; 253: 643–652. Conventional nonsteroidal anti‐inflammatory drugs (NSAIDs), i.e. nonselective cyclooxygenase COX inhibitors have well‐documented nephrotoxicity. Adverse renal effects occur because of inhibition of the synthesis of cyclooxygenase‐derived prostaglandins which act to modulate pathologic processes that would normally impair various renal functions. The introduction of the selective COX‐2 inhibitors raised hope that this class of drugs would reduce injury in both the gastrointestinal tract and the kidneys. Animal and human data, however, suggest that COX‐2 synthesized prostaglandins are important in the modulation of renal physiology during adverse conditions. Hence, it appears that these drugs are equal in causing nephrotoxicity as the nonselective COX inhibitors.

show abstract

“…3 The transformation of nabumetone into the pharmacologically active form MNAA (the latter of the metabolic pathways), occurs by extensive first-pass metabolism. 1,3,8,9 Nabumetone, which has an elimination half-life of approximately 24 h, 10 causes a moderate increase in blood pressure, without change in biological diurnal variation, 11 and has been associated with photosensitivity and skin lesions arising in photoexposed areas in patients treated with the drug. 12,13 MNAA does not undergo enterohepatic recirculation (the process by which a drug is reabsorbed in the gastrointestinal tract after biliary excretion).…”

Section: Introductionmentioning

confidence: 99%

“…The three major metabolic pathways of nabumetone are O-demethylation, reduction to alcohol derivatives, or oxidative cleavage of the side-chain to yield acetic acid derivatives . The transformation of nabumetone into the pharmacologically active form MNAA (the latter of the metabolic pathways), occurs by extensive first-pass metabolism. ,,, Nabumetone, which has an elimination half-life of approximately 24 h, causes a moderate increase in blood pressure, without change in biological diurnal variation, and has been associated with photosensitivity and skin lesions arising in photoexposed areas in patients treated with the drug. , …”

Section: Introductionmentioning

confidence: 99%

Theoretical Study of the Phototoxicity of Naproxen and the Active Form of Nabumetone

Musa

Eriksson

2008

J. Phys. Chem. A

View full text Add to dashboard Cite

Density functional theory using the hybrid functional B3LYP has been employed in order to study the mechanisms of photoinduced decomposition of the closely related nonsteroidal anti-inflammatory drugs naproxen (NP) and 6-methoxy-2-naphthylacetic acid (MNAA; the active form of nabumetone). The photochemical properties and computed energies of various species obtained in this study show that both drugs dominate in their deprotonated forms at physiological pH. The deprotonated acids are unable to decarboxylate from their excited singlets; instead, they decarboxylate from their first excited triplet states with high efficiency, overcoming energy barriers less than 3 and 1 kcal/mol for MNAA and NP, respectively. The ultraviolet and visible spectra of the neutral, deprotonated, and decarboxylated moieties of MNAA and NP are more-or-less similar but with higher probabilites (oscillator strength) for the latter. This fact, as well as the higher reactivity of NP, is explained in terms of the electron-donating effect of the additional methyl group present in NP. Singlet oxygen, superoxide radical anion, and corresponding peroxyl radical species are expected to be formed in different steps throughout the proposed photodegradation pathways of both drugs, which give rise to their effects on biomolecules, for example, lipid peroxidation.

show abstract

The different patterns of blood pressure elevation by rofecoxib and nabumetone

Cited by 15 publications

References 15 publications

Comparison of the COX‐inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee

Comparison of the COX‐inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee

Adverse renal effects of anti‐inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors

Theoretical Study of the Phototoxicity of Naproxen and the Active Form of Nabumetone

Contact Info

Product

Resources

About